Versant Capital Management Inc reduced its stake in Celgene Co. (NASDAQ:CELG) by 46.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 307 shares of the biopharmaceutical company’s stock after selling 266 shares during the period. Versant Capital Management Inc’s holdings in Celgene were worth $28,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds also recently bought and sold shares of the company. FMR LLC boosted its position in Celgene by 89.3% in the first quarter. FMR LLC now owns 16,656,629 shares of the biopharmaceutical company’s stock valued at $1,571,387,000 after buying an additional 7,856,422 shares in the last quarter. Abrams Capital Management L.P. acquired a new stake in shares of Celgene during the 1st quarter valued at $637,066,000. Ruffer LLP acquired a new stake in shares of Celgene during the 1st quarter valued at $226,613,000. Alpine Associates Management Inc. acquired a new stake in shares of Celgene during the 1st quarter valued at $202,076,000. Finally, Boussard & Gavaudan Investment Management LLP acquired a new stake in shares of Celgene during the 1st quarter valued at $186,113,000. Institutional investors own 74.84% of the company’s stock.
CELG traded up $0.82 during midday trading on Friday, hitting $93.87. 4,136,416 shares of the company were exchanged, compared to its average volume of 3,618,393. The firm has a market capitalization of $66.53 billion, a price-to-earnings ratio of 12.34, a P/E/G ratio of 0.43 and a beta of 1.46. Celgene Co. has a 1-year low of $58.59 and a 1-year high of $98.97. The business has a 50 day moving average price of $93.40. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.44 and a quick ratio of 2.66.
CELG has been the topic of several recent research reports. Cowen reissued a “hold” rating and set a $102.00 price objective on shares of Celgene in a report on Tuesday. Barclays lowered Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 price target on the stock. in a research note on Friday, May 3rd. BidaskClub raised Celgene from a “strong sell” rating to a “sell” rating in a research note on Saturday. Mizuho reissued a “buy” rating and set a $103.00 price target on shares of Celgene in a research note on Wednesday, July 3rd. Finally, ValuEngine downgraded shares of Celgene from a “sell” rating to a “strong sell” rating in a research report on Thursday. Two investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $94.81.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Further Reading: How to calculate the intrinsic value of a stock
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.